Human Chorionic Gonadotropin (hCG)

Human chorionic gonadotropin, commonly known as hCG, is a glycoprotein hormone that has become one of the most widely used medications for ovulation induction in mares. Originally derived from the urine of pregnant women and now also available in recombinant forms, hCG mimics the action of luteinizing hormone in horses, making it highly effective for triggering ovulation of mature follicles. This medication has revolutionized equine breeding management by allowing veterinarians to predict ovulation timing with much greater accuracy, thereby optimizing breeding schedules and improving conception rates.

The mechanism of action of hCG in horses relies on its ability to bind to luteinizing hormone receptors on the ovarian follicle. When administered to a mare with a sufficiently mature dominant follicle, hCG triggers the final maturation and rupture of that follicle, releasing the oocyte for potential fertilization. This luteinizing hormone-like activity occurs because hCG and equine luteinizing hormone share structural similarities that allow cross-reactivity at the receptor level. The result is ovulation occurring approximately thirty-six to forty-eight hours following hCG administration in most mares.

Human chorionic gonadotropin is available as a lyophilized powder that must be reconstituted with sterile diluent before administration. The medication is typically given by intravenous or intramuscular injection. Commercial preparations are available in various unit strengths, allowing veterinarians to select appropriate doses for individual patients. Storage requirements and handling procedures must be followed carefully to maintain potency of this biological product.

The safety profile of hCG in mares is generally favorable when used according to established protocols. The medication has been used in equine reproduction for decades with a well-documented history of efficacy and safety. However, repeated use of hCG can lead to antibody formation in some mares, potentially reducing effectiveness over time. This concern has led to the development of alternative ovulation-inducing agents and recommendations for limiting hCG use in individual mares. Veterinary guidance is essential for appropriate patient selection, timing of administration, and monitoring of response.

The primary indication for human chorionic gonadotropin in equine reproduction is the induction of ovulation in cycling mares with adequately developed dominant follicles. This application is fundamental to modern breeding management, allowing veterinarians to predict when ovulation will occur and schedule breeding or insemination accordingly. In natural service breeding programs, this capability helps coordinate mare transport to stallion facilities and optimize the mare's time at the breeding facility. For artificial insemination programs, particularly those using frozen or shipped cooled semen with limited sperm longevity, precise ovulation timing is essential for achieving pregnancy.

Timed artificial insemination programs depend heavily on hCG for their success. When using frozen semen, which has reduced longevity compared to fresh semen, breeding must occur within a narrow window before ovulation. By administering hCG when ultrasonographic examination confirms the presence of a mature follicle, the veterinarian can predict that ovulation will occur approximately thirty-six to forty-eight hours later. This allows scheduling of insemination to achieve optimal timing for sperm-oocyte interaction. Shipped cooled semen programs similarly benefit from predictable ovulation timing to coordinate semen orders and deliveries.

Breeding synchronization for embryo transfer programs represents another important application of hCG. Recipient mares must ovulate in synchrony with donor mares to ensure optimal uterine environment for transferred embryos. By using hCG to control ovulation timing in groups of recipients, veterinarians can maintain a pool of appropriately synchronized mares ready to receive embryos. This application requires careful coordination and monitoring but dramatically improves the efficiency of embryo transfer programs.

Human chorionic gonadotropin is also used to induce ovulation in mares with prolonged estrus or slow follicular development. Some mares display extended heat periods with follicles that are slow to mature and ovulate naturally. Once ultrasonographic examination confirms adequate follicular size, hCG can trigger ovulation and shorten the breeding process. This application is particularly useful late in the breeding season when time is limited and delays in conception further reduce the chances of achieving pregnancy within the calendar year.

Veterinarians select hCG for ovulation induction based on several factors including the mare's reproductive history, follicle size and characteristics, breeding method being used, and previous response to hCG if applicable. The medication is typically not administered until the dominant follicle has reached an appropriate size, generally thirty-five millimeters or larger, though criteria vary among practitioners and individual mares. Mares with history of antibody formation to hCG may require alternative ovulation-inducing agents.

Dosing of human chorionic gonadotropin in mares is based on established protocols rather than strict weight-based calculations, with the standard dose being relatively consistent across mares of varying sizes. The veterinarian determines the appropriate dose and timing based on ultrasonographic evaluation of follicular development and the specific breeding management goals. Proper timing of hCG administration is at least as important as the dose itself, as premature administration to an immature follicle will not result in ovulation while delayed administration may miss the optimal breeding window.

The typical dose of hCG for ovulation induction in mares ranges from one thousand five hundred to three thousand international units, with two thousand five hundred units being a commonly used standard dose. Some veterinarians use lower doses in an attempt to minimize antibody formation while maintaining efficacy. The dose may be adjusted based on mare size, previous response to treatment, and individual veterinarian preference. Research has shown that doses as low as one thousand units can be effective in some mares, though the standard dose range provides more consistent results across the population.

Administration of hCG is typically performed when ultrasonographic examination reveals a dominant follicle of adequate size with appropriate characteristics suggesting impending natural ovulation. Most practitioners use a threshold of thirty-five millimeters or larger, though some mares ovulate smaller follicles naturally and others require larger follicles. The follicle should also display softening of the wall and changes in echogenicity that indicate maturation. Endometrial edema patterns also inform the decision to administer hCG.

The reconstituted hCG solution is administered by intravenous or intramuscular injection. Intravenous administration provides rapid absorption and is commonly used when immediate effect is desired. Intramuscular injection in the hindquarters or neck is an acceptable alternative. The reconstitution and injection should be performed using aseptic technique. The medication should be administered by a veterinarian or under direct veterinary supervision given the importance of proper timing and the consequences of inappropriate use.

Following hCG administration, follow-up ultrasonographic examination is typically performed to confirm that ovulation has occurred. This examination is usually scheduled for approximately forty-eight hours after hCG treatment. If ovulation has not occurred, additional monitoring may be needed and the breeding timing adjusted accordingly. Some mares may not respond to hCG due to antibody formation or inadequate follicular development at the time of treatment.

The importance of appropriate timing and monitoring cannot be overstated when using hCG for breeding management. Premature breeding before ovulation or delayed breeding after ovulation can result in failure to conceive despite appropriate hCG use. Close coordination between the veterinarian, mare owner, and breeding facility ensures that insemination or natural service occurs at the optimal time relative to induced ovulation.

Human chorionic gonadotropin is generally well-tolerated by mares when used appropriately for ovulation induction. Most mares receiving standard doses experience no notable adverse effects beyond the intended ovulation. The medication has a long history of use in equine reproduction with an established safety record. However, as with any biological product administered by injection, the potential for adverse effects exists and mare owners should be informed about monitoring requirements.

The most clinically significant concern with hCG use in mares is the development of anti-hCG antibodies following repeated administration. These antibodies can neutralize subsequently administered hCG, reducing or eliminating its effectiveness for ovulation induction. Studies have shown that antibody formation increases with the number of treatments and that some mares become completely refractory to hCG after multiple exposures. This phenomenon has led to recommendations for judicious use of hCG and limiting the number of treatments per mare per season.

Local reactions at the injection site can occur following hCG administration. Some mares develop transient swelling, sensitivity, or firmness at the injection location, particularly with intramuscular administration. These reactions are typically mild and self-limiting, resolving within a few days without treatment. Persistent or severe injection site reactions should be reported to the veterinarian, as they may indicate infection or unusual sensitivity requiring attention.

Systemic adverse effects from hCG administration are uncommon in horses. Allergic reactions, while rare, can occur with any biological product and would potentially manifest as hives, facial swelling, respiratory distress, or anaphylaxis in severe cases. Any signs of allergic reaction require immediate veterinary attention. Some practitioners pretreat mares with antihistamines if there is concern about sensitivity, though this is not standard practice in most situations.

Rare effects on ovarian function beyond the intended ovulation have been reported. Some mares may develop multiple ovulations following hCG treatment, though whether this represents a drug effect or natural variation is debated. Very rarely, ovarian hyperstimulation or hemorrhagic follicles have been described. Mares that fail to respond to hCG or that have unusual post-treatment findings should receive veterinary evaluation to determine appropriate next steps in the breeding program.

Human chorionic gonadotropin should not be administered to mares with documented hypersensitivity to hCG or to any components of the formulation. Mares that have experienced allergic reactions to previous hCG treatments, including hives, respiratory distress, or anaphylaxis, should not receive additional doses. The development of anti-hCG antibodies, while not an absolute contraindication, significantly reduces the likely effectiveness of treatment and may warrant use of alternative ovulation-inducing agents in affected mares.

Pregnant mares should not receive hCG for ovulation induction purposes, as this would be inappropriate and potentially harmful to early pregnancy. Before administering hCG, pregnancy should be ruled out through appropriate diagnostic testing including ultrasonographic examination. Mares bred in the previous cycle require confirmation of non-pregnant status before receiving hCG treatment in a subsequent estrus. The hormonal effects of hCG during early pregnancy could theoretically interfere with normal pregnancy maintenance.

Mares without adequately developed follicles should not receive hCG, as the medication cannot induce ovulation of immature follicular structures. Ultrasonographic examination confirming the presence of a dominant follicle of appropriate size is a prerequisite for hCG administration. Treating mares during diestrus, anestrus, or early estrus before follicular development would be ineffective and wasteful of medication while potentially disrupting normal ovarian cycling. Proper patient selection through comprehensive reproductive examination is essential.

Certain ovarian abnormalities may contraindicate hCG use or require modified approaches. Mares with ovarian tumors, particularly granulosa cell tumors, would not be appropriate candidates for ovulation induction. Mares with anovulatory follicles that persist through multiple cycles may not respond normally to hCG treatment. Extensive hemorrhagic follicles or ovarian hematomas require healing before attempting further breeding management. The veterinarian evaluates ovarian health and function before recommending hCG treatment.

Human chorionic gonadotropin is frequently used in combination with other reproductive hormones as part of comprehensive breeding management protocols, and understanding these interactions is essential for protocol design. Prostaglandin F2alpha or its analogues are commonly administered earlier in the cycle to lyse the corpus luteum and initiate return to estrus, after which hCG is given later to induce ovulation. These medications do not directly interact but are used sequentially to manipulate different phases of the estrous cycle.

Gonadotropin-releasing hormone products and analogues represent alternative approaches to ovulation induction that may be used instead of or in conjunction with hCG. Deslorelin, available as Ovuplant or in compounded formulations, stimulates endogenous LH release rather than providing exogenous LH-like activity. Some protocols use both GnRH agonists and hCG, though this is less common than using one or the other. In mares that have developed antibodies to hCG, GnRH agonists provide an effective alternative for ovulation timing.

Progesterone and synthetic progestins such as altrenogest are often used as part of breeding management programs but would not typically be administered concurrently with hCG. Progestins suppress estrus and ovulation, which would counteract the intended effect of hCG administration. Protocols using progestins for synchronization would discontinue them before estrus and follicular development, after which hCG might be used for ovulation timing. The timing of these different hormones must be carefully coordinated.

Non-reproductive medications generally do not have significant direct interactions with hCG in horses. Standard medications for health management including anti-inflammatories, antibiotics, and sedatives can typically be administered as needed without affecting hCG efficacy. However, the overall health status of the mare affects reproductive success, and any significant illness or medication needs should be discussed with the veterinarian in the context of the breeding program. Competition horses require attention to withdrawal times for all medications including hCG, which is classified as a prohibited substance under most equestrian federation rules.

Monitoring requirements for mares receiving hCG focus primarily on confirmation of ovulation and assessment of reproductive tract health. Post-treatment ultrasonographic examination is typically scheduled for approximately forty-eight hours after hCG administration to verify that the treated follicle has ovulated. This examination also evaluates the corpus luteum formation and any post-ovulatory fluid accumulation that might affect fertility. If ovulation has not occurred, additional monitoring and potential rebreeding decisions are necessary.

Special consideration is warranted for mares that have received multiple hCG treatments, particularly within the same breeding season or across consecutive seasons. The risk of antibody formation increases with repeated exposure, and mares that have received several treatments may show reduced or absent response to subsequent hCG administration. Some veterinarians recommend limiting hCG use to two to three times per mare per breeding season, though specific recommendations vary. Mares with suspected or documented hCG resistance may require alternative protocols using GnRH agonists.

Competition and performance horse considerations are highly relevant for mares that may return to competition after breeding or that are bred during training periods. Human chorionic gonadotropin is classified as a prohibited substance under Fédération Équestre Internationale rules and most national equestrian federation regulations. Detection times can be prolonged, and mares receiving hCG must observe appropriate withdrawal periods before returning to competition. Racing commissions maintain separate prohibited substance lists with their own testing thresholds. Accurate medication records are essential for compliance.

Handling precautions for hCG include proper storage, reconstitution, and administration technique. The lyophilized powder must be reconstituted with the appropriate sterile diluent according to package directions. Reconstituted solution should be used promptly and any unused portion discarded appropriately. The medication should be stored according to label directions, typically refrigerated, to maintain potency. Human exposure to veterinary hCG does not pose significant risks, but standard medication handling hygiene should be observed.

Long-term considerations for mares receiving hCG include tracking treatment history to identify potential antibody development and adjusting protocols accordingly. Mares that require repeated ovulation induction across multiple breeding seasons may benefit from rotation between hCG and alternative agents such as deslorelin to minimize antibody formation. Complete breeding records including all hormone treatments facilitate appropriate decision-making about future reproductive management.

Proper storage of human chorionic gonadotropin is essential for maintaining the potency of this biological product. The lyophilized powder in unopened vials should be stored refrigerated at temperatures between thirty-six and forty-six degrees Fahrenheit. Some formulations may permit storage at controlled room temperature, but refrigeration generally provides the most reliable stability. The medication should be protected from light and temperature extremes that could accelerate degradation. Check specific product labeling for manufacturer recommendations.

Reconstitution of lyophilized hCG requires sterile technique to prevent contamination. The appropriate sterile diluent, typically bacteriostatic water or normal saline as specified by the manufacturer, is drawn into a sterile syringe and injected into the vial containing the powder. The vial should be gently swirled rather than shaken vigorously to dissolve the powder without excessive foaming. Complete dissolution should be confirmed before drawing the calculated dose. Use of a vented needle or appropriate technique prevents pressure buildup during reconstitution.

Handling of reconstituted hCG solution requires attention to timing and sterility. Once reconstituted, hCG has limited stability and should ideally be used immediately. If storage of reconstituted solution is necessary, it should be refrigerated and used within the timeframe specified by the manufacturer, typically ranging from a few days to one week depending on the specific product and diluent used. Any cloudiness, particulate matter, or discoloration indicates potential degradation and the solution should not be used.

Expiration dates on hCG products should be strictly observed. Biological products can lose potency before the expiration date if storage conditions are not optimal. Using expired or potentially degraded hCG could result in failure of ovulation induction with consequences for the breeding program. Unused or expired medication should be disposed of according to appropriate pharmaceutical disposal guidelines. Veterinary clinics typically have established protocols for disposing of expired biological products.

Draft horse breeds including Clydesdales, Percherons, Belgians, and Shires may have some differences in ovarian dynamics that affect hCG use, though standard doses are generally effective across horse breeds. Draft mares often have larger ovarian structures and follicle sizes compared to light horse breeds, and veterinarians experienced with these breeds adjust their criteria for follicle maturity accordingly. The larger body size of draft horses does not typically necessitate dose increases for hCG, as the medication works at the level of the follicle rather than requiring body-weight-based dosing.

Light horse breeds including Thoroughbreds, Quarter Horses, Arabians, and Warmbloods are the populations in which most hCG research and clinical experience has been accumulated. Standard protocols and expected response times are well-established in these breeds. Thoroughbred and Quarter Horse breeding industries, in particular, rely heavily on hCG for ovulation timing in both natural service and artificial insemination programs. Breed-specific reproductive management differences relate more to breeding season timing and registration requirements than to hCG response per se.

Ponies and miniature horses respond to hCG similarly to full-sized horses despite their smaller body size. Standard doses are typically used, though some practitioners adjust to the lower end of the dose range for very small equines. These breeds may have smaller follicle sizes at ovulation compared to full-sized horses, and veterinarians working with ponies and miniatures adjust their ultrasonographic criteria accordingly. Miniature horse breeding programs use hCG for the same indications as in larger breeds.

Breed-specific reproductive conditions may influence overall breeding management but do not typically affect hCG response directly. Certain breeds have higher incidences of particular reproductive challenges that may require additional diagnostic evaluation or treatment alongside ovulation induction. The veterinarian considers individual mare factors including breed tendencies when developing comprehensive breeding protocols. All breeds benefit from the improved ovulation timing that hCG provides, and the medication remains a cornerstone of equine reproductive management across the diverse equine population.

Deslorelin acetate represents the primary alternative to hCG for ovulation induction in mares. This gonadotropin-releasing hormone agonist stimulates the mare's own pituitary gland to release luteinizing hormone, triggering ovulation through endogenous hormonal pathways. Deslorelin is particularly valuable in mares that have developed antibodies to hCG and no longer respond to that medication. The implant formulation Ovuplant was previously available, and compounded injectable deslorelin preparations are currently used. Response timing with deslorelin is similar to hCG, with ovulation typically occurring thirty-six to forty-eight hours post-treatment.

Other gonadotropins have been used historically for ovulation induction in mares with varying success. Equine chorionic gonadotropin, which has both follicle-stimulating hormone and luteinizing hormone-like activity, is primarily used for superovulation in embryo transfer programs rather than routine ovulation timing. Equine pituitary extract preparations have been used in research settings. Recombinant equine luteinizing hormone represents a theoretical option that would avoid cross-species immunological concerns, though commercial availability has been limited.

Complementary therapies support the success of breeding programs utilizing hCG for ovulation timing. Uterine therapy to address inflammation or fluid accumulation ensures an optimal environment for sperm transport and fertilization. Post-breeding treatments including oxytocin and uterine lavage help clear accumulated fluid and inflammatory debris. Prostaglandins used earlier in the cycle bring mares into estrus with predictable timing, allowing coordinated scheduling of breeding procedures. Progesterone supplementation after breeding may be indicated in certain mares to support early pregnancy.

Comprehensive reproductive evaluation and management maximize the benefit of ovulation induction with hCG. Ultrasonographic monitoring throughout the cycle identifies optimal timing for hCG administration and confirms ovulation has occurred. Breeding soundness evaluation ensures the mare is a suitable candidate for pregnancy. Nutritional management supporting reproductive function provides the foundation for fertility. Veterinary guidance for all aspects of reproductive management ensures appropriate use of hCG and complementary therapies to achieve the goal of successful pregnancy.